New company will focus on developing bispecific antibodies for rare bleeding disorders
British drugmaker will acquire Alexion for approximately $39bn
Updated Date: Tue, 08 Dec 2020 00:00:00 EST
Updated Date: Tue, 08 Dec 2020 00:00:00 EST
Updated Date: Tue, 08 Dec 2020 00:00:00 EST
Updated Date: Tue, 08 Dec 2020 00:00:00 EST
Updated Date: Tue, 08 Dec 2020 00:00:00 EST
David Malcolm Thomas (“Dave”) was born to be a great doctor. He trained at Cambridge and St Thomas’ […]
Chris Jenner, Carly Szasz, Jacqui MartinSetting up a volunteer-to-patient matching projectWith the onset of lockdown, our senior management […]
“R numbers,” “flattening the curve”—if you’d asked the public what these terms meant a year ago, you’d most […]